Retatrutide: The Complete Research Guide

Retatrutide is the most talked-about research peptide of the GLP-1 era, and the reason is simple: it hits a receptor combination nothing else on the market does. Semaglutide agonizes one receptor (GLP-1). Tirzepatide agonizes two (GLP-1 and GIP). Retatrutide agonizes three — GLP-1, GIP, and glucagon — and the early data suggests the addition of glucagon activity delivers weight reduction that outperforms both.

This guide covers what published research says about mechanism, dosing, half-life, and how it compares to the rest of the incretin class. Everything here is for laboratory reference. Retatrutide is supplied strictly for research use and is not approved for human consumption.

Mechanism: why three receptors

Weight regulation in the body involves more than appetite. The three receptors retatrutide targets each contribute a different piece:

• GLP-1 agonism — slows gastric emptying, enhances insulin secretion, reduces appetite via hindbrain signaling. This is the dominant mechanism in semaglutide and liraglutide.
• GIP agonism — potentiates insulin secretion and appears to modulate fat metabolism in adipose tissue. GIP activity is what separates tirzepatide from semaglutide.
• Glucagon agonism — increases resting energy expenditure and promotes hepatic lipid oxidation. Historically avoided (glucagon raises blood glucose), but in combination with GLP-1/GIP the glucose-raising effect is offset and the metabolic-rate effect dominates.

In simpler terms: GLP-1 and GIP reduce energy intake; glucagon increases energy expenditure. Retatrutide works on both sides of the equation.

Published clinical data

The landmark Phase 2 trial (Jastreboff et al., New England Journal of Medicine, 2023) tested retatrutide in adults with obesity over 48 weeks:

For comparison, the STEP trials of semaglutide 2.4 mg landed around −15% at 68 weeks, and SURMOUNT-1 for tirzepatide 15 mg reported ~−20.9% at 72 weeks. Retatrutide's 48-week numbers at the top dose exceed both, and the curve hadn't clearly plateaued at study end — suggesting further loss with extended treatment.

Phase 3 trials (TRIUMPH-1 through -4) are in progress and are the basis for potential future FDA submission.

Half-life and dosing cadence

Retatrutide has a reported half-life of approximately 6 days, supporting once-weekly subcutaneous administration. This is similar to semaglutide (~7 days) and tirzepatide (~5 days). Steady-state is typically reached after 4–5 weeks at a given dose.

Research protocols in published studies escalate doses over time to reduce gastrointestinal side effects:

• Weeks 1–4: 2 mg weekly
• Weeks 5–8: 4 mg weekly
• Weeks 9–12: 8 mg weekly
• Week 13+: 12 mg weekly (top dose in the Phase 2 trial)

Reported nausea incidence at the top dose was meaningful but comparable to other GLP-1 class agents; most researchers in trials tolerated escalation without discontinuation.

Reconstitution reference

Our catalog vial is 10 mg. A standard 2 ml bacteriostatic water reconstitution yields 5,000 mcg/ml. A 2 mg research dose = 0.4 ml = 40 units on a U-100 insulin syringe, which fits in a 0.5 ml syringe.

Retatrutide vs tirzepatide vs semaglutide

For a deeper comparison see our semaglutide vs tirzepatide vs retatrutide breakdown.

Side effect profile (reported in trials)

• Gastrointestinal — nausea, diarrhea, constipation. Dose-dependent and concentrated in the first 4–8 weeks of any escalation step.
• Increased heart rate — ~3–6 bpm resting increase reported at top doses, likely driven by glucagon agonism and elevated metabolic rate.
• Mild injection site reactions — local only, generally resolve without intervention.

Serious adverse events in Phase 2 were uncommon and did not differ meaningfully from the broader incretin class. Long-term safety data is limited pending Phase 3 readouts.

Why researchers are watching this one

Three reasons retatrutide is the peptide to pay attention to in 2026:

1. Magnitude. 24% at 48 weeks is the highest reported weight-loss number for any pharmaceutical weight-management agent in modern trials.
2. Mechanism breadth. Glucagon activity introduces the first weight-loss drug that meaningfully increases energy expenditure rather than purely suppressing intake — a qualitatively different metabolic lever.
3. Curve shape. Unlike semaglutide and tirzepatide, the Phase 2 weight-loss curve had not visibly plateaued at the 48-week endpoint. Whether that continues in Phase 3 is the biggest open question.

Key references

• Jastreboff AM et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." NEJM 389:514–526 (2023).
• Coskun T et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist…" Cell Metabolism 34:1234–1247 (2022).
• Rosenstock J et al. "Retatrutide in type 2 diabetes — Phase 2 trial." The Lancet 402:529–540 (2023).